Small-Cap Biotech Stocks Are Having a Rough Year, But That Could Change in a Heartbeat

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.

While the world's leading biotech companies — churning out Covid-19 vaccines and treatments — have hit record share prices, their small-cap rivals have been sinking. But some analysts say the latest figures suggest a bargain in the sector.

Pfizer's share price hit a record high for the first time in 20 years this month, topping $48, while vaccine partner BioNTech and rival vaccine producer Moderna have witnessed triple-digit gains in 2021. But all that success overshadows the struggles of other biotech stocks:

Continue reading

Source Fool.com